

**Michigan Pharmacy and Therapeutics Committee
Meeting of December 6, 2005 Minutes
DRAFT Kellogg Center, East Lansing MI, 6PM DRAFT**

I. Introductions and approval of minutes of September 13, 2005 meeting

Khan Nedd, M.D. was appointed Chairman of the Committee by the Governor and conducted this meeting.

Members present were Drs. Nedd, Fiechtner, Bradley, Robins, Inman, Arend, Dorfman, and Perri. Staff present were Annette Paul, RPh., Susan Moran, Bureau of Medicaid Program Operations and Quality Assurance, Donald Quillan, and George Baker, MD. The minutes of the September 13 meeting were approved.

II. Public comment : new Rx, CNS, Analgesic classes

The following individuals made presentations to the Committee

- B. Amann, MD, Sepracor, Lunesta®
- Lynn Walker, MD, Mark Folts, PAC, Takeda Pharmaceuticals, Actoplus Met®
- R. Bulten, MD, Johnson and Johnson, Concerta®
- J Albert, RN and CDE, Amylin, Byetta®
- Raymond Cole, MD, Roche, Boniva®
- Jay Gandhi, PharmD, Sanofi-Aventis, AmbienCR®
- C. Cooper, PharmD, Schering Plough, Asmanex®
- V. Rozas, MD, Abbott, Zemplar®

III. New Drug Reviews

Following review of the materials and discussion of each drug product, the Committee made the following recommendations to the Department:

Asmanex®-Add to the MPPL and to the PDL category "Inhaled Systemic Glucocorticoids" without prior authorization

Boniva®-Add to the MPPL and to the PDL category "Osteoporosis Agents: Bisphosphonates" with prior authorization required.

Byetta®- Add to the MPPL and create a new category in the PDL under the Diabetes section for "Incretin Mimetics"; no prior authorization; the Department will instruct First Health to edit for the presence of other diabetic treatments in the beneficiary's paid claims before processing the Byetta® claim. If there are no other treatments for diabetes present, then the prescriber will have to call for authorization to explain the rationale for its use.

Xibrom®-Add to the MPPL without prior authorization

Zemplar®- Add to the MPPL without prior authorization

IV. Line Extensions

Following review and discussion, the Committee made the following recommendations to the Department:

Kaletra 50mg-200mg®: Add to MPPL without prior authorization

Ketek 300mg®: Add to the MPPL and to the PDL category of "Ketolides" without prior authorization

Clobex Spray®: Add to the MPPL with prior authorization

Natelle C®: Add to the MPPL but place a limit on reimbursement equal to the other pre-natal vitamin screens

ActoplusMet®: Add to the MPPL and to the PDL category “Oral Hypoglycemics-Biguanide combinations” without prior authorization

V. Review of PDL Classes

Analgesics: Narcotics, long, intermediate and short acting; COX II inhibitors

Central Nervous System: Alzheimer’s Dementia; Anti-anxiety-general; Bi-polar disorders; Drugs for ADHD; Sedative hypnotic non-barbiturates

Following presentations by the workgroup chairs, Drs. Fiechtner and Bradley, and discussion by the Committee, the following recommendations were made:

The Committee recommended the Department keep the current classification of drugs in the **Central Nervous System** and **Analgesic** classes as they appear on the 10/1/2005 PDL, i.e., **no changes to the list of drugs requiring prior authorization and those available without prior authorization.**

For the short acting opioid analgesics, especially those combined with acetaminophen, the Department will place a maximum daily quantity limit to reflect the maximum daily recommended consumption of acetaminophen as it would apply to the particular product; the Department will monitor beneficiaries who have prescriptions for over three months continuous use of one or more of these products; further prescriptions for such a beneficiary will require the prescriber to explain his/her pain management goals, why other long acting agents are not suitable, any consultation with pain management specialists, use of urine screening for validation of use and other parameters.

For the sedative hypnotic non barbiturates, the Department will monitor beneficiaries who have prescriptions for over three months continuous use of one or more of these agents; further prescriptions for those beneficiaries will require prior authorization with an explanation of the need for continued use, exclusion of depression or other treatable conditions.

VI. Scheduling of meeting dates for 2006

The meeting dates for 2006 will be as follows:

Tuesday, March 7, June 6, September 12 and December 5

VII. Workgroups for next meeting: ACEIs, ARBs, CCBs

These drug classes from the PDL will be reviewed for discussion at the March 7, 2006 meeting.

VIII. Public comment for drug classes to be reviewed at next meeting

The following individuals made public comment concerning drug products scheduled for review at the March 7, 2006 meeting:

S. Moody, PharmD, AstraZeneca, Atacand®

W. Gibson, MD, Abbott, Tarka®

D.Iacobellis, PharmD, Pfizer, Caduet®

The Committee thanked Annette Paul, RPh., First Health Services Corporation, for all her contributions and excellent work in assisting with the P and T meetings since 2002, and wished her success in her new position within First Health.

